NewGenIvf Group (NASDAQ:NIVF) & Oncology Institute (NASDAQ:TOI) Head-To-Head Survey

NewGenIvf Group (NASDAQ:NIVF) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

NewGenIvf Group has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.

Valuation and Earnings

This table compares NewGenIvf Group and Oncology Institute”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$5.43 million	0.21	-$520,000.00	N/A	N/A
Oncology Institute	$393.41 million	0.94	-$64.66 million	($0.68)	-5.84

NewGenIvf Group has higher earnings, but lower revenue than Oncology Institute.

Analyst Recommendations

This is a breakdown of current ratings and price targets for NewGenIvf Group and Oncology Institute, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1	0	0	0	1.00
Oncology Institute	1	0	2	1	2.75

Oncology Institute has a consensus price target of $7.00, indicating a potential upside of 76.32%. Given Oncology Institute’s stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than NewGenIvf Group.

Profitability

This table compares NewGenIvf Group and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Oncology Institute	-13.21%	-1,527.21%	-35.20%

Summary

Oncology Institute beats NewGenIvf Group on 7 of the 13 factors compared between the two stocks.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.